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Status and Prospects of Genetic Disease
A. E. RETIEF
TABLE I. CLASSIFICATION OF GENETIC TRAITS
ACCORDING TO DOMINANT, RECESSIVE AND X-LINKED
MODES OF INHERITANCE"
in these categories reflect the degree of variability in man
and provide a useful guide in the search for the basic
defects in genetic disorders.
SUMMARY
The current status of our knowledge of genetic diseases
is reviewed. The incidence of monogenic, multifactorial
and chromosomal disorders, according to the literature
to date', is given, and the possibilities of mass screening
programmes are discussed. The prospects for' antenatal
diagnosis of genetic diseases are reviewed, with emphasis
on the indications for amniocentesis and the safety of
the procedure. Finally, speculations are made regarding
the possible effeCts of medical and social practices on the
frequency of genetic disorders in future generations.
S. AIr, med, l., 54, 849 (1978).
Phenotype
Autosomal dominant
AutoS()mal recessive
X-linked
Total
Number
classified
583 (+635)
466 (+481)
93 (+78)
1142 (+1194)
Total
1 218
947
171
2336
Biology has been revolutionized only during the past
20 - 30 years and we still know relatively little about
human biology, particularly human genetics. Thus the
genetic determinants of normal traits as well as of com-
mon diseases and birth defects are largely unknown.
During the past 2 decades the role of genetics in the
aetiology of disease has become more and more apparent.
It has been estimated that 4 - 5'% of livebom infants
suffer from genetic or partly genetic disorders.' -· As in-
fectious diseases decline in frequency and environmental
conditi.ons improve, genetic disease becomes relatively
more Important as a cause of mortality and morbidity.
Carter" has shown that the frequency of congenital
abnormalities, as a cause of infant mortality, has increased
from about 5'% to 20'% in the last 70 years. Roberts
et al." found that of the total number of deaths of
children in hospital, over 4<J% were genetic or partly
?en.etic in origin. Recent data from paediatric hospitals
mdlcate that 20 - 3<J% of inpatients have genetic
diseases,"-1. the majority being polygenic disorders with
a few single gene or chromosomal anoma1ies.
INCIDENCE OF GENETIC DISEASES
Monogenic Disorders
A great variety, of monogenic conditions exists, most
of which are individually rare. Many of tbem are not
obvious at birth, and many are difficult to diagnose.
McKusick" listed the known dominant, recessive and
X-linked phenotypes in man. Table I shows the numerical
status of the classification of genetic traits under dominant
recessive and X-linked modes of inheritance. The entrie~
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In each of the categories in Table I the phenotypic
traits are either classified as being quite certain, or in-
cluded because the suggestions for the particular mode
of inheritance are strong enough to warrant inclusion
(numbers in parentheses).
The total number of loci identified by these categories
is a very small proportion of the total number of genes
in man. The number of structural genes - those that
determine the amino acid sequence of polypeptide chains
of proteins, and which occur in single copies so that
mutations behave in a Mendelian manner - may be of
the order of 50000."-1< With a total of 1 142 'proven'
traits, the categories reveal perhaps about 2'% of the total
structural genes. Carter" recently collated studies of the
frequencies of individual monogenic conditions which
were carried out by workers with special interests in a
particular condition.
Dominant Conditions
The total frequency of the more common dominant
conditions in Caucasoid populations is 6/1 000 live-births.18
One-third of these are caused by monogenic hyper-
cholesterolaemia. Tbe less common dominant conditions
are given as 0,3/1 000 live-births. Carter" concluded that
7/1 000 would be a reasonable figure for all presently
known serious dominant conditions.
Recessive Conditions
Autosomal recessive conditions which appear to bave
birth frequencies in Britain of about, or greater tban,
~,1 /1 .000 were compiled and the total of about 2,5 /1 000
hve-brrths for tbe presently known recessive conditions
is given.18
Among the few recessive conditions in which mental
retardation is preventable by early diagnosis and treat-
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ment, are certain inborn errors of metabolism. It was not
possible to estimate the frequency of these disorders in
the general population until results of mass screening of
newborn infants became available."'" Abnormalities of
amino acid metabolism occur in about 1 in 100 newborn
infants.""· Most of these are considered to be temporary
(and presumably benign) but about 1 in 3 000 result in
a permanent defect."
X-linked Conditions
The total frequency of X-linked conditions compiled
by Carter" is given as 0,5 /1 000 male births, and he
concluded that the total of all X-linked conditions presently
known might be of the order of 0,8/1 000 live-births.
Total Frequency of Monogenic Conditions
The total birth frequencies of presently known serious
and moderately serious monogenic conditions are about
1%.
Multifactorial Diseases
The multifactorial model assumes that .there are many
genetic loci and many environmental factors involved in
the cause of the disease. Most of the more common
diseases are polygenic or multifactorial in their inheritance,
and the frequency in the population affected by these
diseases is of the order of 2 - 3'% or more.""
Chromosome Anomalies
A considerable proportion of heritable diseases in man
results from the presence of constitutional chromosome
anomalies which fall into broad categories: (I) those where
an abnormal number of chromosomes are present; and (ii)
those where there is an abnormal chromosome structure.
Estimates from studies on large numbers of con-
secutive neonates indicate that for disorders arising from
chromosome number anomalies, the incidence is about
5/1 000, and those resulting from chromosome structural
rearrangements about 2/1 000."·03 Of the total number of
chromosomal anomalies about half (3/1 000) involve the
autosomes and a further 3/1 000 the sex chromosomes
- a total of 6 - 7/1 000 live-births. These figures represent
information obtained by means of conventional chromo-
some staining techniques. With the advent of the new
banding techniques, more structural anomalies are ex-
pected to be found, increasing the frequency in this
category. No large survey on a newborn population,
utilizing the new techniques, has yet been published. The
total ·frequency of chromosome disorders in the live-born
is estimated at 10/1 000 or l%."
GENETIC SCREENING
Genetic screening is defined as a search in a population
for individuals possessing certain genotypes.
Screening for Disease
The object of the search is to find the persons who
have specific genetic diseases, or who have the genotypes
that in special circumstances may lead to disease, in order
to provide treatment or medical management to reverse
or prevent the adverse effects of their disorders.
Today 90% of all babies born in the USA are tested
for phenylketonuria (PKU). Mass screening for this disease
was begun, not for genetic reasons; but as a means of
eliminating one form of mental retardation. Experience
with PKU has served as a model for the screening of
newborn infants for other metabolic disorders. The results
of a recent survey,'" indicate that State support in the
USA of mass neonatal screening has rapidly increased
during the past 2 years. The number of States engaged in
screening for galactosaemia has risen to 17. At least 9
States screen for histidinaemia, 11 for homocystinuria,
12 for maple syrup urine disease and 10 for tyrosinaemia.
Twelve States indicated that they screen some neonates
(presumably Blacks) for sickle cell anaemia, and 7 of these
test some infants for l3-thalassaemia.
An example of mass screening of a selected population
is the programme which began in the USA in 1971, the
object being to discover couples at risk and to reduce
the incidence of Tay-Sachs disease by selective abortion.'"
Tay-Sachs disease is a recessive disorder occurring in
Ashkenazi Jews with a frequency of 1/3600. The carrier
state is as high as 1 in 30 Jews.
The most effective screening programmes are those used
for detectifig genetic diseases whose frequency is relatively
high in the newborn population. Among the dominant
conditions, the frequency at birth of hyperlipidaemia is
estimated to be as high as 2/1 000 live-births." Goldstein
et aT. n ..,. produced evidence of 3 monogenic forms, namely,
hypercholesterolaemia, hypertriglyceridaemia, and a third
in which serum levels of both metabolites are elevated.
With current methods, screening would have to be carried
out several times - during infancy, childhood and young
adult life. While experimental studies are underway to
distinguish the genetic from the non-genetic causes of
hyperlipidaemia, and the single gene and multigene types,
a practical alternative for physicians would be to study
the offspring of individuals manifesting any of these 3
disorders."" Dietary regulation for any individual found
to have raised lipid levels might then be tried.
Cystic fibrosis is another condition which occurs in
1 in 2 000 newborn infants." In a selected population
in South West Africa, it has been reported to occur in
lout of every 622 newborn babies." Although the treat-
ment of this disease is only supportive, there is no question
that the life expectancy has been increased and the burden
reduced for patient and family. Strenuous efforts are being
made to find a test for detecting affected infants before
the onset of symptoms, particularly in the newborn
period."'"
Screening for genetic diseases has not yet had much
impact on the awareness or the health of the public.
PKU screening may be judged to have been successful
in the USA in the prevention of mental retardation.
Sponsors of screening plans have pointed out that in addi-
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tion to the prevention of tragedy in a family, the cost
of the screening programme is significantly less than the
cost of caring for a single patient with PKU during his
lifetime. There are still significant weaknesses in some
PKU screening programmes. A good screening effort
requires more than a low-cost, high-accuracy method to
identify presymptomatic infants. At the very least, pro-
vision should be made for guaranteeing access to good
medical care, providing reliable counselling to the parents
of the affected infants and protecting the confidentiality
of the screening records. Many countries lack the required
logistic system to reach and follow-up each child. To
screen for rare genetic diseases at a .time when malnu-
trition and infectious diseases are the principal problems
would be a waste of resources. Perhaps screening could
be limited to relatively small populations in which the
particular disease occurs at a high frequency.
ANTENATAL DIAGNOSIS OF GENETIC
DISEASES
At the present time, analysis of cultivated fetal cells can
provide a firm 'diagnosis for essentially all known chromo-
somal disorders. The observation by Brock and Sutcliffe"
that fetal- neural tube defects (anencephaly and open spfna
bifida) are associated with elevated levels of alpha-feto-
protein in amniotic fluid, has widened the scope for pre-
natal monitoring. Milunsky and Atkins" have reported
that at present, at least 71 inborn errors of metabolism
can be diagnosed prenatally, and in 28 of these, a firm
diagnosis has been reported in the literature.
Indications for Amniocentesis
Amniocentesis for early prenatal diagnosis of certain
abnormalities is now an established part of clinical genetic
practice and antenatal care. Apart from the experience
of single units, several collaborative studies from North
America and Europe have been reported. Polani and
Benson36 collected the results of over 1 700 amniocenteses
from published reports as well as from" personal enquiries.
The results of about 1 500 antenatal diagnoses from 41
centres in North America were reported by Milunsky."
Lindsten et al.38 reported the results from 6 large centres
in Europe, and the latest review published by Galjaard'"
was on 6 121 cases from 46 of the major Western European
countries.
From these studies the present indications for diagnostic
amniocentesis to detect cytogenetic disorders are: (0
advanced maternal age; (h) previous child with Down's
syndrome; (iii) family history of Down's syndrome; (iv)
family history of other chromosome abnormalities; (v)
one of the parents carrying a balanced translocation; and
(vi) fetal sex determination because of the likelihood
of one of the X-linked disorders. The results of these data
further indicate that the risk of a fetus having either
trisomy 21 or some other chromosome anomaly is about
5'% for mothers over the age of 38." If one of the parents
is a carrier, the chance of an unbalanced translocation in
the fetus is about 1%. For the other cytogenetic indi-
cations, the risk is often less than 1,5'%, but here the
value of amniocentesis lies in relieving parental anxiety.
Other reasons for amniocentesis are to detect inborn
errors of metabolism. Out of the total of 6121 amnio-
centeses, 206 were performed for enzyme defects where
the risk of the fetus was 1 in 4. The 206 analyses were
done for 23 different enzyme defects.3D Amniocentesis will
also detect a neural tube defect such as anencephaly or
spina. bifida aperta. From a total of 2708 pregnancies, 81
fetuses with anencephaly or spina bifida were detected by
alpha-fetoprotein analysis.
Safety of Amniocentesis
More specific investigations into the technique and safety
of amniocentesis have been published by the National
Institute of Health in the USA" and the Canadian Medical
Research Council." The evidence so far suggests that the
procedure carried out at about 16 weeks in a major
health centre is safe, accurate and reliable when monitored
by ultrasound. Under these circumstances, the miscarriage
rate seems to be no greater than that in control preg-
nancies.
Eugenic Effects of Antenatal Diagnosis.
Antenatal diagnosis will contribute to the lowering of
the frequency of a genetic disease in the current geceration.
The effect on subsequent generations will be mostly bene-
ficial (or eugenic) although in som~ situations it may
be deleterious (or dysgenic).
The contribution of genotypes to future generations
depends on their relative fitness. If their fitness is not zero
and their frequency in the population not reduced to
zero by antenatal diagnosi~, then the frequency of the
abnormal allele in the next generation, although reduced,
will not be zero. Therefore, the reduction in gene fre-
quency for dominant and X-linked conditions in future
generations will be substantial, although smaller for re-
cessive conditions.
Deleterious effects of antenatal diagnosis may arise if
families tend to replace fetuses diagnosed as affected with
other children - so-called reproductive compensation.
For dominant conditions, there should be no dysgenic
effects because antenatal diagnosis and compensation for
affected genotypes should lead to only normal children
being born. In autosomal recessive conditions, two-thirds
of children compensating for affected genotypes will be
carriers, therefore an increase in the frequency of the ab-
normal allele may result." Effects of antenatal diagnosis
for X-linked disorderswiII depend on the possible appli-
cations of antenatal diagnosis, namely: (I) abortion of
affected males and carrier females; (if) abortion of affected
males; and (iif) abortion of all males from carrier mothers.
In the first instance, the frequency of abnormal alleles
will be reduced to a new equilibrium depending on the
mutation rate and the proportion of carrier women ascer-
tained. Abortion of affected males, with full reproductive
compensation, will lead to a new equilibrium with the
frequency of carrier females being about 1,5 times the
original rate. The abortion of all males from carrier
mothers with full reproductive compensation is more dys-
genic, since Carrier mothers will contribute an equal pro-
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portion of normal and abnormal genes to their daughters
with no elimination of abnormal genes. Mutations will
continually add new abnormal genes to the gene pool.
The gene frequency will rise linearly with time at a rate
equal to the mutation rate, which will lead to doubling
of the gene frequency every two generations.
Antenatal diagnosis will contribute to the lowering
of the frequency of chromosomal and multifactorial con-
ditions in the current generation. Its effects on the fre-
quency in future generations will be small since the re-
currence risks are normally low.
GENETIC COUNSELLING
Genetic counselling is a process of communication, con-
cerning the occurrence and the risks of recurrence of
genetic disorders within a family. The aim of counselling
is to enable a couple or a person to make rational
decisions about whether or not to reproduce.
The first prerequisite in genetic counselling is a firm
diagnosis of the disease," and in single gene or multi-
factorial disorders, a thorough pedigree study. In simple
Mendelian disorders, the mode of inheritance is known
and recurrence risks can be derived from genetic theory
even for complex family histories." The recurrence risks
for' multifactorial diseases are not the simple Mendelian
ratios, and the best available estimates are the empirical
risks - the observed frequency of the disease in relatives
of affected patients. In practice, however, these risks may
vary with the sex, severity and age of onset in affected
individuals and with the number of affected members in
the family concerned. New methods of estimating re-
currence risks for multifactorial conditions have been
developed," and these can be used in genetic counselling
to supplement empirical risks in complex situations. Com-
puter programmes are also available for calculating re-
currence risks for use in genetic counselling...·., Tables of
recurrence risks estimated from a multifactorial model
of liability to some common congenital malformations
have been calculated."
Although some follow-up studies"'" have suggested
that those who have been counselled grasp the meaning
of risk and avoid reproducing if the risk of having affected
children is high, some data have indicated that the meaning
pf genetic risk may not always be well understood."""
Most counsellors put the interest of the patient and his
fatnily before the interests of society and the State, and
pursue medical rather than eugenic objectives. Untoward
effects on society may be pointed out, but most coun-
sellors do not usually attempt to give advice based on the
consideration. of the gene pool. Genetic counselling has
thus traditionally been non-directive, It is usually main-
tained that every family situation is different and that
the meaning of a given risk varies from family to family,
so that in some cases, a future pregnancy may be justified
even with high recurrence risks.
. EFFECTS OF MEDICAL AND SOCIAL
PRACTICES ON THE FREQUENCY OF
GENETIC DISORDERS
In the past many workers have studied the effects of various
factors on the human gene pool.""'" The emphasis ha
usually been on single factors with dysgenic effects and
on long-term changes and the time to reach new equilibria.
In recent years, a number of new medical practices such
as improved treatment for affected individuals, genetie
counselling, population screening and social customs, such
as family limitation or selective abortion, have been intro-
duced and are being widely adopted. Not all of these are
dysgenic and some have eugenic effects on the gene pool.
Because of the very complicated interaction of the strate-
gies and tendencies, it is not easy to make any realistic
prediction of their overall long-term effects. The dysgenic
effects are usually predicted without consideration of
compensatory eugenic effects. From the results of Holloway
and Smith," in studies of the effects of a variety of
practices used and their overall effect on the gene pool,
there generally seems to be little cause for alarm about
the deleterious effects of the new medical and social
practices being adopted.
The main deleterious effect may be from improved
reproductive fitness, for example, by surgical treatment for
dominant and X-linked diseases, which can lead to sub-
stantial increases in gene frequency and in disease in
future generations. If, however, therapy is cheap and
effective, the burden of the disease to the individual and
to society is slight. If the therapy is expensive or not very
effective, families will seek ways to prevent recurrence
of the disease. In recessive disorders, a small reduction
in the average fitness of carriers detected by ·population
screening and antenatal diagnosis would outweigh any
deleterious effects of other practices such as 'selective
abortion and reproductive compensation. The dysgenic
effects will occur in a term so long that it exceeds any
reasonable projection of the time when the relatively
crude methods of prevention and treatment will be re-
placed by better methods, based perhaps to a greater
degree on gametic rather than zygotic selection."
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Xerographic Parenchyma) Patterns and Breast Cancer
D. M. BREBNER, E. E. EPSTEIN, M. LANGE
SUMMARY
The xerographic mammography records of 3 002 patients
with breast disease were reviewed and classified according
to the criteria of Wolfe. The parenchymal P2 pattern oc-
curred in 59% of patients with cancer and in only 16,9%
patients under the age of 40 without cancer, but the inci-
dence of the DV pattern was much the same in patients
with cancer and in those without cancer in almost all the
age groups studied. The incidence of the P2 pattern tended
to rise slightly in patients without cancer, whereas the
incidence of the DV pattern tended to remain the same in
all groups. The findings of Wolfe and others have been
confirmed by this study, which also supports the sug-
gestion that women under the age of 40 undergo a baseline
xerographic examination of the breasts for cancer and that
subsequent screening be based on the presence of a P2
pattern. This will involve a selection of 16,9% of the un-
der 40-year-old subjects without cancer who might, on
screening, be expected to show 60% of the cancers in each
decade after the age of 40. This information coupled with
other factors indicating a high risk for the development of
breast cancer, such as florid epithelial dysplasia, a previous
history of breast cancer or a family history of breast can-
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cer, should increase the yield of early carcinomas at a
preclinical stage and reduce costs of a screening pro-
gramme.
S. A fr. med. l., 54, 853 (1978).
The mortality of breast cancer, which has remained
unchanged for a long time, can be lowered by early
detectioh of the malignant lesion, and the most impor-
tant technique for this is mammography.l The appli-
cation of screening techniques, including mammography,
to the total number of women at risk is prohibitively
expensive, and doubts have been raised about the possible
risk of inducing breast cancer in young women by the
frequent use of routine mammography; although a number
of authors have indicated that the danger from this type
of radiation exposure has been grossly overstated.' Ex-
perience gained from screening projects in the USA
proves that the number of cancers detected in an open
screening programme is low.
More effective use can be made of screening techniques
by confining these to women at high risk of developing
breast cancer. A number of factors are associated with
such a high risk. They include the age of the patient,
a family history of breast cancer, nulliparity, a first preg-
nancy late in life, previous cancer in the contralateral
breast, marked epithelial hyperplasia on biopsy, an adverse
hormone milieu, hypothyroidism, impaired immunological
competence, chronic psychological stress and exposure to
radiation.
Wolfe has reported yet another high-risk factor, namely
